133 results about "Elevated creatinine" patented technology

The invention belongs to the technical field of nano-enzymes, and particularly relates to a preparation method and application of a porous RuO2 nano-enzyme for detecting creatinine. Comprising the following steps: ultrasonically dispersing Ca (NO3) 2.4 H2O, RuCl3 and glycine in deionized water to obtain a mixed solution A; dissolving sodium alginate in deionized water, and uniformly stirring to obtain a mixed solution B; injecting the mixed solution B into the mixed solution A, slowly stirring to form bimetallic hydrogel, washing with deionized water, and freeze-drying to obtain a solid A; calcining the solid A to obtain a solid B; and adding the solid B into hydrochloric acid for ultrasonic dispersion, stirring for a period of time, and centrifugally washing and drying the precipitate in vacuum to obtain the loose and porous RuO2 nano-particles. The nanoparticles prepared by the invention have abundant pore structures and great specific surface area, active sites can be fully exposed, and the POD enzyme activity is remarkably improved.

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

The application discloses a composition for protecting liver and strengthening kidney and reducing uric acid, which is made of the following raw material components: Anoectochilus roxburghii, dried tangerine or orange peel, chicory, gardenia, turmeric, Hovenia dulcis Thunb, Cistanche deserticola Y.C.Ma, Rehmannia glutinosa, potassium citrate, sodium citrate and goose myo-peptide. The composition combines the immortal concept of TCM (Traditional Chinese Medicine) "treating disease from the root" and the uric acid control method of modern nutritional medicine as an organic whole, and achieves multiple effects of protecting liver and strengthening kidney, mutual benefit of yin and yang and reducing uric acid through multiple action targets. Animal experiment results show that the composition can effectively reduce the activities of transaminase ALT and AST, relieve liver damage, reduce serum creatinine level and improve urea ammonia excretion rate, improve kidney function, inhibit the activities of xanthine oxidase and adenosine dehydrogenase and reduce uric acid level. The composition is safe and has no toxic side effects, is suitable for people with insufficient liver and kidney functions and hyperuricemia and has a wide application prospect.

The invention relates to the technical field of clinical decision support and medical data intelligent analysis, in particular to a critical patient individualized liquid resuscitation decision support system, which is characterized in that a data acquisition unit acquires pulse pressure variation waveform and multi-dimensional physiological data of each stroke volume; a volume benefit analysis channel of the dynamic decision-making unit segments a respiratory cycle, extracts pulse pressure fluctuation characteristics, outputs a per-stroke volume increase probability value through a machine learning classifier, an organ injury early warning channel calculates a blood lactic acid and creatinine clearance rate change rate, and generates an acute kidney injury risk sign in combination with inferior vena cava image verification; the execution control unit sends an infusion control or limit instruction according to the combined state; and the feedback optimization unit adjusts the weight of the model according to the actual value of blood lactic acid removal, and recalculates the probability value, so that individualized precise resuscitation, balance capacity benefit and organ protection are realized, and the treatment safety and effectiveness are improved.

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

This invention provides a continuous method for preparing high-purity creatine monohydrate, comprising the following steps: a) adding chloroacetic acid aqueous solution dropwise to an aqueous methylamine solution, stirring at room temperature for 2 hours after the addition is complete; b) heating to 50-60°C and holding for 1 hour to remove most of the methylamine, then heating to 95°C to evaporate the methylamine aqueous solution for 1 hour; c) adding sodium hydroxide solution dropwise to the solution from step b) at 95°C, then heating to 105°C and concentrating under reduced pressure for 1.5 hours to approximately half the original volume, obtaining a creatine solution with a concentration of 30%-40%; d) cooling the solution from step c) to 40-60°C and adding a catalyst; e) drying to obtain pure creatine monohydrate. This invention reduces the methylamine equivalent, saving costs, and eliminates the need for purifying creatine for direct use in the next reaction; it can simultaneously lower the system reaction temperature and pH value to inhibit the formation of byproducts dicyandiamide and creatinine, and eliminates the need for debittering agents for purification and debittering, thus saving production costs.

The invention relates to the technical field of data analysis, and particularly discloses a data analysis method and system for acute kidney injury, and the method comprises the steps: integrating the multi-source acute kidney injury data of a patient, including clinical information and historical medical records, constructing the time series data of serum creatinine, urine volume and the like, extracting the risk features in an unstructured text by using an NLP technology, and analyzing the risk features in the unstructured text. Physiological index dynamic and semantic risk factors are deeply fused through space-time alignment, a basic feature vector is formed, a difference risk score of historical and current states is calculated in combination with sliding window features of historical medical records, when the score exceeds a preset threshold value, it is judged that a dynamic evolution risk exists, an advanced intervention instruction is automatically generated, and early intervention is achieved. Therefore, the problems of single data dimension, risk identification lagging and untimely intervention of a traditional method are solved.

The invention belongs to the technical field of reproductive medicine and clinical metabolism intervention, and particularly relates to a group of markers for diagnosing unexplained recurrent abortion and application thereof. Aiming at the clinical pain point that unexplained recurrent abortion (URSA) lacks accurate metabolic typing diagnosis indexes and targeted treatment means, based on detection of a large number of clinical samples and verification of cell experiments, direct association between down-regulation of levels of choline related metabolites and trimethylamine oxide (TMAO) of decidua tissues and the RSA is disclosed for the first time; the core effect of TMAO in-situ synthesis of decidua stromal cells (DSC) in regulation and control of the decidualization process is determined; meanwhile, an RSA indication screening system of joint detection of serum creatinine and decidua choline metabolism is constructed, a targeted TMAO targeted intervention scheme is formed in a matched mode, a diagnosis and treatment closed loop of RSA from precise typing to targeted treatment is achieved, and a brand new technical path is provided for clinically solving the URSA diagnosis and treatment problem.

It suppresses the decrease in creatine content over time. [Solution] The cosmetic composition contains zinc element (A), creatine (B), and creatinine (C).

An application for the EGT-AuNPs in preparing contrast agents and / or antioxidants is provided, where the EGT-AuNPs include gold nanoparticles (AuNPs), the AuNPs are connected to L-ergothioneine (EGT) by gold-sulfur bonds, and the antioxidants include medicines for preventing and / or treating acute kidney injury (AKI). EGT-AuNPs with antioxidant activity are designed and synthesized through the combination of the higher imaging contrast of gold and the antioxidant natural product EGT, and they are ultra-small AuNPs, which achieve the combination of CT imaging and antioxidant effects, and are suitable for renal imaging, particularly for the early diagnosis and treatment of AKI, realizing the integration of diagnosis and treatment, circumventing the toxicity of contrast agents present in the conventional nanomaterials, lowering the serum creatinine and urea nitrogen levels, and reducing the degree of renal tubular damage.

The invention discloses a biomarker, application of the biomarker in predicting the risk of diabetic nephropathy and a kit, which can realize non-invasive efficient evaluation on the severity of diabetic nephropathy and provide important supplement for early diagnosis and refined risk stratification of diabetic nephropathy. The ratio of the Sulfatase-1 to the creatinine Cr is uSULF1 / Cr, and the Sulfatase-1 and the creatinine Cr are both from urine.

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

The invention relates to the technical field of medical information systems, in particular to a nursing system for tumor patients in a chemoradiotherapy period, which comprises a physiological monitoring module, a threshold evaluation module, a path switching module, a task decomposition module and a nursing scheduling module. According to the method, by continuously collecting multi-dimensional physiological data such as the heart rate, the blood oxygen saturation degree, the blood pressure and the serum creatinine of the patient and conducting noise suppression processing, stable bearing state information can be obtained, and dynamic quantitative evaluation of the tolerance degree is achieved in combination with deviation analysis of the nursing base line; the nursing task is subjected to priority and rhythm adjustment when the bearing index exceeds the limit, the high-load task is split by utilizing fluctuation prediction, and the interval duration is set, so that the risk caused by physiological burden concentration is reduced, the nursing execution rhythm matched with the real-time state of a patient is formed, and the flexibility of load distribution and the instantaneity of intervention response are realized. And the accuracy and safety of whole-course nursing are improved.

The invention belongs to the technical field of analytical chemistry, and discloses a method for detecting creatinine in a creatine product, which comprises the following steps: (1) precisely weighing a sample, adding a buffer solution, carrying out vortex oscillation dissolution, volume metering, shaking up, centrifuging, and passing through a water phase filter membrane to obtain a creatine test solution; (2) a creatine test solution is taken, a liquid chromatograph is adopted for liquid phase detection, and the liquid chromatography conditions are as follows: an SCX chromatographic column is adopted, an ammonium dihydrogen phosphate solution is taken as a mobile phase for isocratic elution, an ultraviolet detector is adopted, and the content of creatinine is obtained according to a liquid phase detection result. According to the method, the situation that the detection result of the creatinine in the creatine product is virtually high can be remarkably reduced, accurate quantification of the creatinine byproduct creatinine is achieved, and a more perfect data basis is provided for quality control of the creatine product.

According to the RNA binding protein HuR inhibitor and the anti-fibrosis application thereof, the compound provided by the invention has obvious inhibitory activity on HuR protein, has a good anti-renal fibrosis effect, can obviously reduce protein and mRNA expression levels of fibronectin (FN1) and alpha-smooth muscle actin (alpha-SMA), can improve renal function impairment, and can be used for preparing the anti-fibrosis medicine for treating renal fibrosis. The levels of blood urea nitrogen (BUN) and creatinine (Cr) which are commonly used for evaluating the renal function are reduced, and the compound can be used for preparing the medicine for treating the chronic kidney disease.

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.

The invention discloses application of a BTK inhibitor in preparation of a medicine for treating acute kidney injury and complications thereof. The invention provides a new strategy for treating acute kidney injury and complications thereof by using a BTK inhibitor, and particularly relates to application of the BTK inhibitor as an acute kidney injury medicine. The invention finds that serum creatinine and urea nitrogen levels can be effectively reduced by knocking out mouse BTK, and kidney injury is relieved and conversion from AKI to CKD is delayed or prevented by recovering kidney pathological structure and reducing apoptotic cell generation, which indicates that BTK is an effective target for treating acute kidney injury. Meanwhile, through treatment of an acute renal ischemia-reperfusion model, it is found that the BTK inhibitor such as ibrutinib can relieve ischemia-reperfusion induced renal function impairment and improve the renal function of a mouse, and it is indicated that the BTK inhibitor can serve as a treatment scheme for acute renal injury.

The invention discloses a detection method and a kit for calculating the ratio of serum (plasma) complements C3, C4 and C5 and urine complements C3, C4 and C5 to urine creatinine, which are innovatively developed on a full-automatic analyzer with a touch screen. The method realizes full-automatic detection of an instrument, is simple, convenient and rapid to operate, has stable and reliable performance of the kit, is a good helper for targeted prevention and treatment of complement-related diseases and clinical accompanying diagnosis and treatment, and opens up a new direction for clinical application of multi-item detection of an in-vitro diagnostic technology complement system.

Techniques includes measuring, using a creatine sensor, a creatine sensor current signal (ΔI2) of a first calibration solution (CS2). A creatine sensor sensitivity (Slope) for the creatine sensor is based on the creatine sensor current signal (ΔI2). The first calibration solution (CS2) has a known concentration of creatine (CR_CS2), a known concentration of creatinine (CREA_CS2), and a stable ratio of creatine to creatinine over a range of temperatures for a predefined shelf-life of the first calibration solution (CS2). The Techniques include measuring, using the creatine sensor, a measured creatine concentration (MCR_CS3) of a second calibration solution (CS3). The second calibration solution (CS3) has an initial known creatine concentration (CR_CS3), an initial known creatinine concentration (CREA_CS3), and an unstable ratio of creatine to creatinine that changes over the predefined shelf-life. Concentrations of creatine and creatinine in a sample are thereafter estimated.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention belongs to the field of biological medicines, and particularly discloses application of extracellular vesicles EVs carrying CD35 functional molecules in preparation of medicines for treating sepsis-related multi-organ injury, preferably, the EVs are derived from human podocytes or other cells or tool cells capable of naturally or engineered expressing CD35, and the EVs are administrated through caudal vein injection and can be used for preparing medicines for treating sepsis-related multi-organ injury. Normal saline is taken as a carrier, and the dosage of 1 * 10 < 10 > EVs each time is once every 12 hours and twice continuously. It is proved for the first time that EVs carries CD35 to inhibit circulation mononuclear cell complement activation (the EVs are combined with C3b to block downstream complement cascade reaction), migration of mononuclear cells to the kidney, the heart, the liver and the lung is reduced, and therefore multi-organ inflammation damage and cell apoptosis are relieved. In a cecum ligation perforation (CLP) sepsis model, it is proved that the medicine significantly improves the survival rate of mice, improves renal functions (reduces creatinine / urea nitrogen) and kidney pathological tissue damage, and meanwhile relieves pathological damage of multiple organs of the heart, the liver and the lung. The invention provides a new treatment strategy and drug candidate for sepsis-related multi-organ dysfunction.

The invention relates to a human urine creatinine detection standard substance as well as preparation and valuing thereof. The preparation method comprises the following steps: processing and preparing the standard substance; checking the uniformity of the urine creatinine standard substance; testing the stability of the urine creatinine standard substance; determining a standard value of the urine creatinine standard substance by a high performance liquid chromatography-isotope dilution mass spectrometry method; and performing statistical calculation on the affirmed value of the urine creatinine standard substance and performing uncertainty evaluation on the affirmed value result. The invention provides a preparation and valuing method of a urine creatinine standard substance aiming at the problem that the urine creatinine detection result is inaccurate and incomparable because no human urine creatinine standard substance exists at present, so that the preparation and valuing method of the urine creatinine standard substance is used for developing a urine creatinine detection reagent, verifying the performance of the method and tracing the quantity value of the urine creatinine detection result. The accuracy and comparability of clinical urine creatinine detection results are ensured, and clinical examination of diseases such as chronic kidney diseases is facilitated.

The invention belongs to the technical field of bioengineering, and particularly relates to a construction method and application of an animal model of infant renal consumption disease. According to the construction method of the animal model for the infant type renal consumptive disease, provided by the invention, the renal tubule NPHP3 gene of an experimental animal is knocked out to obtain the animal model of which the renal tubule NPHP3 gene is specifically knocked out, and the animal model is recorded as Nphp3flox / -and Cdh16-Cre +. Nphp3flox- / -and Cdh16-Cre + mouse models have obvious renal cyst and interstitial fibrosis 2 weeks after growth, serum creatinine and urea nitrogen increase from 3 weeks, and more than 5-8 weeks of death, so that compared with previously reported genetic engineering mice, the model better conforms to clinical characteristics of human infant renal consumption diseases, and a foundation is laid for subsequent research on pathogenesis and intervention effect.

The invention discloses a three-enzyme-inorganic hybrid nanoflower as well as a preparation method and an application method thereof, and belongs to the technical field of enzyme immobilization. The three enzymes in the material are creatininase, creatinase and sarcosine oxidase, and the carrier is calcium phosphate. According to the three-enzyme-inorganic hybrid nanoflower, creatininase, creatinase and sarcosine oxidase are loaded on the same carrier, and the three-enzyme-inorganic hybrid nanoflower can be generated on the surface of a working electrode in situ and can also be directly dropwise added to the surface of the working electrode for electrochemical precise detection of creatinine. The method has the advantages of being simple in operation, green, environmentally friendly and the like, and the prepared three-enzyme-inorganic nanoflower material is high in stability and rapid in detection and has a good application prospect in the field of biosensing.

For the purpose of determination for the selection of intravesical BCG instillation therapy, the present invention comprises measuring 2-ethylhydracrylic acid-2, arabinonic acid-2, carnitine, lauric acid, myristic acid, octanoylcarnitine, paraxanthine, S-methylcysteine, S-methylcysteine-S-oxide, SDMA, theobromine, indole-3-acetic acid, pentanoic acid, 1-methyl-4-imidazoleacetic acid, ADMA, alanine, argininosuccinic acid, choline, citrulline, creatinine, guanidoacetic acid, lysine, methionine sulfoxide, myristic acid, N-(1-deoxy-1-fructosyl)leucine, N-acetylneuraminic acid, N6,N6,N6-trimethyllysine, propionylcarnitine, threonine, gamma-glutamyl-glycine, gamma-glutamyl-tyrosine, and gamma-glutamyl-valine in blood, serum, or plasma.

The invention provides a method of diagnosing overactive bladder disorder (OAB), the method comprising: measuring the concentrations of one or more of adenosine triphosphate (ATP), acetylcholine (ACh), nitric oxide (NO) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP / Cr to 0.000001; ACh / Cr to 0.1; NO to 20000; IL-5 / Cr to 100; wherein the likelihood of having OAB (pOAB)=1 / 1+e−x, where X=one or more of the following: (a) (−2.688±1.050)+5.472±2.098×subject's age+1.356±0.559×Gender (Female=1, Male=0)+(−7.998±40.273)×[IL-5 / Cr]; (b) (−2.141±0.966)+4.506±1.902×subject's age+1.034±0.519×Gender (Female=1, Male=0)+(−5294.063±9075.456)×[ACh / Cr]; (c) (−2.825±1.072)+5.964±2.167×subject's age+1.312±0.562×Gender (Female=1, Male=0)+17.790±58.762×[IL-5 / Cr]+(−9180.821±12700.057)×[ACh / Cr]; (d) (−2.993±1.197)+5.580±2.309×subject's age+1.724±0.719×Gender (Female=1, Male=0)+63.571±73.444×[IL-5 / Cr]+(−0908.523±13606.752)×[ACh / Cr]+(−566.991±636.589)×[ATP / Cr]; (e) (−3.090±1.200)+5.393±2.256×subject's age+1.797±0.717×Gender (Female=1, Male=0)+34.767±56.331×[IL-5 / Cr]+(−562.743±629.316)×[ATP / Cr]; or (f) (−2.650±1.067)+5.516±2.120×subject's age+1.389±0.583×Gender (Female=1, Male=0)+(−4.060±45.238)×[IL-5 / Cr]+(−1.456±6.833)×[NO / Cr]; and wherein a pOAB above a threshold indicates that the subject has a high likelihood of having or developing OAB and a pOAB below a threshold indicates that the subject does not have OAB.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic nephritis and a preparation method and application thereof. The traditional Chinese medicine composition for treating chronic nephritis is prepared from the following raw materials in parts by weight: radix angelicae sinensis, roasted rhizoma atractylodis macrocephalae, radix stephaniae tetrandrae, radix saposhnikoviae, poria cocos, herba epimedii, fructus rosae laevigatae, radix astragali and rhizoma curcumae. After a chronic nephritis patient is treated by the traditional Chinese medicine composition, indexes such as serum creatinine and 24-hour urine protein can be remarkably improved, clinical symptoms are remarkably relieved, and a better product is provided for treating the chronic nephritis patient.

The invention discloses an application of a fibroblast growth factor 2 in preparation of a medicine for preventing and / or treating calcium oxalate kidney stone, and breaks through the technical prejudice that FGF-2 mainly promotes renal fibrosis in the prior art. It is found and proved for the first time that exogenous supplement FGF-2 can play a significant therapeutic effect in a calcium oxalate kidney stone model. Animal experiments prove that through intraperitoneal injection of FGF-2 (0.1 mg / kg / day), calcium salt crystal deposition in kidney tissue can be effectively reduced (Von Kossa dyeing verification), structural damage of renal tubular epithelial cells is relieved, inflammatory response is inhibited (HE dyeing verification), and meanwhile the serum creatinine and urea nitrogen level is remarkably improved. The invention provides a brand new molecular target and drug strategy for treatment of kidney stone, can be used as an effective auxiliary scheme of the existing physical lithotripsy technology, and reduces the risk of stone residue and recurrence.